Advertisements



Amarin: New Vascepa Prescriptions Grow After REDUCE-IT"s Topline Results

Amarin: New Vascepa Prescriptions Grow After REDUCE-IT"s Topline Results.....»»

Category: topSource: seekingalphaNov 9th, 2018

Why Amarin Shares Are Exploding

Amarin shares absolutely skyrocketed on Monday after the company announced topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT. Needless to say, the results were very........»»

Category: blogSource: 247wallstSep 24th, 2018

Amarin Trades Down After Release Of Late-Stage Vascepa Trial Results

Amarin Corporation plc (NASDAQ: AMRN) shares were falling Monday following the presentation of detailed primary results from the the late-stage REDUCE-IT study that evaluated Vascep read more.....»»

Category: blogSource: benzingaNov 12th, 2018

Amarin: In Good Position To Capitalize On Exceptional REDUCE-IT Results

Amarin: In Good Position To Capitalize On Exceptional REDUCE-IT Results.....»»

Category: topSource: seekingalphaDec 10th, 2018

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association Conference Call (Transcript)

Amarin Corporation PLC (AMRN) CEO John Thero Presents Primary REDUCE-IT Trial Results Following Presentation at 2018 Scientific Sessions of American Heart Association Conference Call (Transcript).....»»

Category: topSource: seekingalphaNov 13th, 2018

Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released

Amarin Goes From Solid To Speculative After Full REDUCE-IT Trial Results Released.....»»

Category: topSource: seekingalphaNov 12th, 2018

Amarin's REDUCE-IT Trial: Something Fishy? - Seeking Alpha

STATAmarin's REDUCE-IT Trial: Something Fishy?Seeking AlphaAMRN provided an update on the REDUCE-IT trial of Vascepa; the NEJM provided an online article a.....»»

Category: topSource: googlenewsNov 11th, 2018

Amarin"s Stock Soars as Fish Oil Drug Lowers Heart Risks

Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa. Shares of Amarin Corporation p.....»»

Category: personnelSource: nytSep 27th, 2018

42 Stocks Moving In Monday"s Mid-Day Session

Gainers Amarin Corporation plc (NASDAQ: AMRN) shares jumped 232.4 percent to $9.94 after the company's REDUCE-IT cardiovascular study of Vascepa in LDL-C patients met its primary endpoint. read more.....»»

Category: blogSource: benzingaSep 24th, 2018

Amarin"s REDUCE-IT study on-track to report results before end of September

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 26th, 2018

Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations

REDUCE-IT™ Study On-Track for Reporting Top-Line Results by the End of September 2018 Management to.....»»

Category: earningsSource: benzingaAug 1st, 2018

Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations

REDUCE-IT Study On-Track for Reporting Top-Line Results.....»»

Category: earningsSource: benzingaMay 2nd, 2018

Amarin: Waiting For REDUCE-IT Results

Amarin: Waiting For REDUCE-IT Results.....»»

Category: topSource: seekingalphaApr 11th, 2018

Rising trading revenue lifts Goldman"s results

Goldman Sachs swung to a quarterly profit from a loss, and those earnings topped expectations. It was the only Wall Street bank to grow its trading revenue. Fred Katayama reports......»»

Category: videoSource: reutersJan 16th, 2019

Alcoa (AA) to Report Q4 Earnings: What"s in the Offing?

Initiatives to reduce complexities of operations and strengthen balance sheet are expected to be conducive to Alcoa's (AA) fourth-quarter results. However, hig.....»»

Category: dealsSource: nytJan 14th, 2019

The Wall Street Journal: GM Raises Profit Guidance for 2018

General Motors raised its profit guidance for 2018 ahead of reporting full results next month, and said its bottom line should grow in 2019 as it expects auto demand to remain resilient in its two biggest markets, China and the U.S......»»

Category: topSource: marketwatchJan 11th, 2019

Amarin CEO hints at stronger 2019 outlook for Vascepa sales, STAT News reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 9th, 2019

Amarin: Vascepa Revenues Could Be Significantly Higher Than $350 Million In 2019

Amarin: Vascepa Revenues Could Be Significantly Higher Than $350 Million In 2019.....»»

Category: topSource: seekingalphaJan 8th, 2019

Amarin Provides Preliminary 2018 Results and 2019 Outlook

U.S. Sales Force Increased to 400 Sales Professionals for 2019 Following Unprecedented Positive Results of Vascepa® Cardio.....»»

Category: earningsSource: benzingaJan 4th, 2019

Amarin down 7% after below-consensus FY19 revenue view on Vascepa sNDA timing

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 4th, 2019

Manitowoc to Grow on Strong Order Flow, High Input Costs Ail

Manitowoc's (MTW) focus on cost controls, product innovation will drive results despite inpu.....»»

Category: smallbizSource: nytDec 24th, 2018